Sepsis Program Governance Under a Board Deadline
A 420-bed nonprofit hospital has a risk-adjusted sepsis mortality rate of 18.4%, compared with a national benchmark of 14.1%. The board quality committee sets a target of 20% relative reduction within 12 months and allocates $350,000. The quality director must choose among three proposals: a $200,000 EHR sepsis alert, a $150,000 nurse-led screening protocol with 2.0 FTE, or a $90,000 physician education campaign. Current bundle compliance is 61%; lactate measurement within 3 hours is 54%; antibiotic administration within 1 hour for septic shock is 72%. The CMO insists on physician-led change; nursing leadership wants standardized screening; the CFO wants a business case with ROI. The quality committee meets monthly and has no defined decision rights for cross-department conflicts. Two prior improvement efforts stalled after four months.
1. Recommend a governance structure and decision rights for the sepsis program, and justify how it will prevent the prior stall.
Read the worked answer
Recommendation: create a three-tier structure. (1) Executive steering committee: CMO, CNO, CFO, quality director, ED and ICU medical directors, pharmacy, lab, and IT. Meets monthly; owns scope, budget, and cross-department conflicts. (2) Operational working team: project manager, nurse champions, physician champion, data analyst, and infection prevention; meets weekly. (3) Frontline improvement huddles in ED and ICU.
Decision rights: use a RACI matrix. Steering decides budget reallocation, protocol changes affecting multiple departments, and escalation of missed milestones. The working team decides PDSA tests within approved scope. The quality director owns measurement definitions and reporting. Medical staff committees retain formal approval for clinical protocols, so engage them early.
Why this prevents stall: prior efforts stalled because no forum could resolve cross-department trade-offs and no executive owned the work. A charter with a single accountable executive, explicit escalation within 14 days, and monthly dashboard review creates accountability. Include a conflict-resolution rule: if steering cannot agree, CMO and CNO co-decide with CFO consulting on affordability. Publish decisions to frontline teams to reduce rumor and rework.
2. Evaluate the three proposals and propose a sequenced portfolio within the $350,000 budget. State assumptions and measures.
Read the worked answer
Evaluation: the EHR alert alone is the weakest first move: high fixed cost, likely alert fatigue, and it does not fix the 54% lactate and 61% bundle reliability. Education alone is necessary but insufficient; it changes knowledge, not workflow. Nurse-led screening directly addresses early recognition and can be tested quickly, but 2.0 FTE at $150,000 consumes 43% of the budget.
Portfolio: fund nurse-led screening ($150k) plus physician and nurse education ($60k) plus small EHR order-set and reporting changes ($40k), leaving $100k contingency. Sequence: months 1-2, charter and baseline data; screen in ED with nurse-driven protocol and lactate order; month 3, education with case reviews; months 4-6, add an EHR prompt only for high-risk patients after workflow is reliable. Assumptions: 2.0 FTE can be recruited; lab can add stat priority; medical staff approves the protocol. Measures: screening completion, lactate within 3 hours, cultures before antibiotics, antibiotic within 1 hour for shock, bundle compliance, sepsis mortality, ICU length of stay, alert override rate, and cost per case. Review monthly with SPC charts.
3. The board asks for a 20% relative mortality reduction in 12 months. Assess whether this target is realistic and what leading measures you would report quarterly.
Read the worked answer
Assessment: 18.4% to 14.7% is a 3.7-point absolute reduction. With roughly 600 sepsis admissions per year, that is about 22 fewer deaths; plausible with reliable bundle delivery, but mortality is a lagging, low-frequency outcome and may fluctuate. A 12-month target is ambitious but not impossible if baseline bundle compliance is 61% and lactate measurement is 54%; those gaps suggest substantial preventable harm. However, do not promise the mortality target from process gains alone; case mix, coding, and timing of recognition affect it.
Quarterly reporting: lead with leading measures: sepsis screening completion, lactate within 3 hours, blood cultures before antibiotics, antibiotic within 1 hour for septic shock, 30 mL/kg fluid for hypotension, and bundle compliance within 3 and 6 hours. Add balancing measures: ED length of stay, alert fatigue, antibiotic overuse, and ICU capacity. Use statistical process control and report mortality as a rolling 12-month risk-adjusted rate with confidence intervals. If mortality does not move by month 9 despite process improvement, review measure validity before blaming teams.